The crystal growth kinetics of amorphous celecoxib (CEL), an anti-inflammatory BCS class II drug, was systematically investigated for developing effective stabilization strategies to enhance solubility of CEL. In comparison to the bulk, the surface crystal growth was much faster, e.g., ?80-fold higher at (Tg +3) °C. Both surface and bulk growths near and below Tg were accelerated over those predicted from a diffusion-limited process, which are attributed to solid-state crystal growth and glass-to-crystal growth mechanisms, respectively. These two growth modes were disrupted by fluidity differently upon heating, with a much wider transition zone on the surface in comparison to the bulk. In fact, the surface transition zone of CEL is the widest among all systems studied so far. The phenomenon of cross-nucleation was also observed between CEL polymorphs, forms I and III, which exhibited different crystal growth rates in the diffusion-controlled region both on the surface and in the bulk.